You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 2020415415204
Nov 202021321569
Dec 202010310334
Jan 202114914838
Feb 2021777730
Mar 202110410470
Apr 2021838345
May 202110410479
Jun 2021727252
Jul 2021858569
Aug 2021606042
Sep 2021636331
Oct 2021828253
Nov 202112812862
Dec 2021555538
Jan 2022647148
Feb 2022606240
Mar 2022909131
Apr 2022838946
May 2022828238
Jun 2022919327
Jul 2022949627
Aug 2022879028
Sep 2022818526
Oct 2022697252
Nov 2022515211
Dec 2022636519
Jan 2023616127
Feb 2023787838
Mar 20239910334
Apr 2023474723
May 2023595920
Jun 2023585820
Jul 2023636541
Aug 2023535217
Sep 2023575723
Oct 202311611615
Nov 202332933021
Dec 202310310428
Jan 2024575836
Feb 2024606031
Mar 20249910086
Total404740901769